An interventional study of PechaKucha-Based Symptom Management Education and Routine/Standard Patient Education in Cancer and Neoplams, sponsored by Istanbul Aydın University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Istanbul Aydın University · Not applicable, Interventional, and Supportive care
This randomized controlled study aims to evaluate the effect of education delivered using the PechaKucha method on symptom management and quality of life in patients receiving chemotherapy. Participants will be randomly assigned to either an intervention group or a control group.
Participants in the intervention group will receive individual education on symptom management during chemotherapy using the PechaKucha method. The education will be delivered as a video presentation consisting of 20 visual slides and lasting 6 minutes and 40 seconds. Participants in the control group will receive routine/standard patient education.
Symptom severity and quality of life will be assessed before the education and one week after the intervention using the Edmonton Symptom Assessment System (ESAS) and the EQ-5D. The study will compare changes in symptom severity and quality of life between the intervention and control groups to determine whether PechaKucha-based education is effective in supporting symptom management and quality of life among patients receiving chemotherapy.
This randomized controlled experimental study is designed to evaluate the effect of education delivered using the PechaKucha method on symptom management and quality of life in patients receiving chemotherapy. The study is being conducted in the Chemotherapy Unit of Health Sciences University Kanuni Sultan Süleyman Training and Research Hospital, with participant enrollment beginning in June 2026.
Participants will be assigned to an intervention group or a control group. Participants in the intervention group will receive individual education on "Symptom Management During Chemotherapy," delivered by the researchers using the PechaKucha method. The educational intervention will be presented as a video consisting of 20 visual slides with a total duration of 6 minutes and 40 seconds. The educational content addresses common chemotherapy-related symptoms and problems, including pain, nausea, anemia, fatigue, diarrhea, constipation, risk of infection, anxiety, depression, mucositis, and alopecia. Participants in the control group will receive routine/standard patient education.
Data will be collected through face-to-face interviews. At baseline, participants in both groups will complete the Patient Information Form, the Edmonton Symptom Assessment System (ESAS), and the EQ-5D. One week after the intervention, the ESAS and EQ-5D will be administered again to participants in both groups. The Patient Information Form, which is used to obtain demographic and clinical information, will be administered only at baseline.
Between-group comparisons will be performed using the independent-samples t-test or Mann-Whitney U test, as appropriate. Within-group pretest-posttest comparisons will be performed using the paired-samples t-test or Wilcoxon signed-rank test, as appropriate. Statistical significance will be set at p \< 0.05.
Before participation, individuals will receive written and verbal information about the study, and informed consent will be obtained from all participants.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 140 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Istanbul Aydın University is the lead sponsor of 70 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm will receive individual education on "Symptom Management During Chemotherapy" delivered by the researchers using the PechaKucha method. The education will be provided as a video presentation consisting of 20 visual slides with a total duration of 6 minutes and 40 seconds. The educational content covers pain, nausea, anemia, fatigue, diarrhea, constipation, risk of infection, anxiety, depression, mucositis, and alopecia.
Behavioral: PechaKucha-Based Symptom Management Education
Participants in this arm will receive routine/standard patient education provided as part of usual care in the chemotherapy unit. No PechaKucha-based education will be provided to participants in this group.
Behavioral: Routine/Standard Patient Education
The intervention consists of individual education on symptom management during chemotherapy delivered by the researchers using the PechaKucha method. The education is provided as a video presentation consisting of 20 visual slides, with each slide displayed for 20 seconds, for a total duration of 6 minutes and 40 seconds. The educational content addresses pain, nausea, anemia, fatigue, diarrhea, constipation, risk of infection, anxiety, depression, mucositis, and alopecia.
Participants assigned to the control group will receive routine/standard patient education provided as part of usual care in the chemotherapy unit. This education does not include the PechaKucha-based symptom management education provided to the intervention group.
Change in Symptom Severity Assessed by the Edmonton Symptom Assessment System (ESAS)
The Edmonton Symptom Assessment System (ESAS) will be used to assess symptom severity in patients receiving chemotherapy. Participants rate the severity of each symptom on a numerical scale, with higher scores indicating greater symptom severity. The intervention group will receive symptom management education using the PechaKucha presentation format, whereas the control group will receive the same educational content using a conventional teaching method. Both groups will also receive a brochure summarizing the educational content. ESAS will be administered to both groups at baseline and one week after the intervention. Changes in symptom severity from baseline will be compared between the groups.
Time frame: Baseline (before the intervention) and one week after the intervention
Plan to share: No — There is no plan to share individual participant data (IPD).
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 6 months is below that.
Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Aydın University